EU regulatory institutions are inquiring about Novo Nordisk's acquisition of catalent.
According to sources, on November 14, the European Union's antitrust regulatory agency has requested feedback from pharmaceutical industry competitors and customers on four business areas regarding Novo Holdings' plan to invest $16.5 billion in acquiring Catalent. Novo Holdings, the controlling shareholder of Danish pharmaceutical company Novo Nordisk A/S, has become the highest market cap company in Europe driven by the generous profits from the popular weight loss drug Wegovy. While survey results show that the European Commission is seeking market insights, it may allow competitors and customers to raise potential antitrust concerns.
Unusual Options Activity: NVO, CSCO and Others Attract Market Bets, NVO V/OI Ratio Reaches 754.9
EST Nov 13th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
EU Regulators See Info From Rivals, Customers in Catalent Sale to Novo Holdings - Reuters
Hims & Hers Launches GLP-1 Drug Shortage Tracker
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
European Equities Traded in the US as American Depositary Fall in Wednesday Trading